ZENITH DRUGS LIMIT Stock Price Today (NSE: ZENITHDRUG)
Fundamental Score
ZENITH DRUGS LIMIT Share Price — Live NSE/BSE Price, Fundamentals & Analysis
ZENITH DRUGS LIMIT share price today is ₹41.35, down 1.55% on NSE/BSE as of 22 September 2026. ZENITH DRUGS LIMIT (ZENITHDRUG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹89.95 (Cr). The 52-week high for ZENITHDRUG share price is ₹73.45 and the 52-week low is ₹33.30. At a P/E ratio of 21.62x, ZENITHDRUG is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 5.77% and a debt-to-equity ratio of 0.74.
ZENITH DRUGS LIMIT Share Price Chart — NSE/BSE Historical Performance
ZENITH DRUGS LIMIT share price chart: 5.95% return over the past month. 52-week high ₹73.45, 52-week low ₹33.30.
ZENITH DRUGS LIMIT — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹42.10 | ₹42.65 | ₹41.80 | ₹42.00 | 7.20K (Cr) | |
| ₹43.50 | ₹44.05 | ₹43.25 | ₹43.25 | 4.00K (Cr) | |
| ₹43.50 | ₹43.50 | ₹42.00 | ₹43.45 | 11.20K (Cr) | |
| ₹45.95 | ₹45.95 | ₹42.50 | ₹43.15 | 1.90L (Cr) | |
| ₹47.80 | ₹47.80 | ₹45.00 | ₹46.10 | 6.40K (Cr) | |
| ₹46.50 | ₹47.85 | ₹46.50 | ₹47.85 | 3.20K (Cr) | |
| ₹48.10 | ₹48.10 | ₹46.35 | ₹46.35 | 2.40K (Cr) | |
| ₹48.85 | ₹48.85 | ₹47.45 | ₹48.10 | 7.20K (Cr) | |
| ₹46.00 | ₹51.00 | ₹45.50 | ₹48.85 | 57.60K (Cr) | |
| ₹42.00 | ₹46.40 | ₹42.00 | ₹45.45 | 24.00K (Cr) |
ZENITH DRUGS LIMIT — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹41.40 | ₹51.00 | ₹39.80 | ₹42.00 | +1.45% | |
| ₹46.15 | ₹47.80 | ₹40.10 | ₹42.10 | -8.78% | |
| ₹46.00 | ₹54.35 | ₹43.50 | ₹47.80 | +3.91% | |
| ₹47.95 | ₹47.95 | ₹38.25 | ₹46.10 | -3.86% | |
| ₹39.65 | ₹49.00 | ₹37.00 | ₹47.95 | +20.93% | |
| ₹38.00 | ₹45.90 | ₹37.50 | ₹39.95 | +5.13% | |
| ₹47.00 | ₹49.00 | ₹33.30 | ₹35.20 | -25.11% | |
| ₹50.00 | ₹52.05 | ₹44.50 | ₹49.50 | -1.00% | |
| ₹51.90 | ₹56.35 | ₹45.00 | ₹54.80 | +5.59% | |
| ₹52.55 | ₹57.20 | ₹48.00 | ₹50.20 | -4.47% | |
| ₹65.05 | ₹65.05 | ₹49.80 | ₹54.70 | -15.91% | |
| ₹62.60 | ₹67.90 | ₹60.00 | ₹65.05 | +3.91% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
ZENITH DRUGS LIMIT Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
ZENITH DRUGS LIMIT Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZENITHDRUG across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Attractive Valuation (P/E: 21.62 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (41.70%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (19.03% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Balanced Promoter Holding (69.98%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (5.77%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.05%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Interest Coverage (2.00x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-66.56 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
ZENITH DRUGS LIMIT vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare ZENITH DRUGS LIMIT with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
ZENITH DRUGS LIMITZENITH DRUGS LI...Selected✓ ZENITHDRUG • | 39.5/100 | ₹41.35₹41 | ₹89.95₹89.95 | 21.62Average 21.6 Average | 5.77%Poor 5.77% Poor | 9.05%Poor 9.05% Poor | 0.74Good 0.7 Good | 6.27%Good 6.27% Good | 19.03%Excellent 19.03% Excellent | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
ZENITH DRUGS LIMIT Quarterly Performance
Latest quarterly metrics for ZENITHDRUG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
41.70%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-4.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
19.03%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
6.27%
Compounded annual net profit growth over 5 years
ZENITH DRUGS LIMIT Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZENITHDRUG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
ZENITH DRUGS LIMIT Financial Statements
Annual income statement, balance sheet and cash flow for ZENITH DRUGS LIMIT (ZENITHDRUG) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for ZENITH DRUGS LIMIT
About ZENITHDRUG (ZENITH DRUGS LIMIT)
ZENITH DRUGS LIMIT (ZENITHDRUG) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a c...urrent market capitalisation of ₹89.95 (Cr). ZENITH DRUGS LIMIT has delivered a Return on Equity (ROE) of 5.77% and a ROCE of 9.05%. The debt-to-equity ratio stands at 0.74, reflecting the company's capital structure. Investors tracking ZENITHDRUG share price can monitor key metrics including P/E ratio, promoter holding of 69.98%, and quarterly earnings growth.
Company Details
ZENITHDRUG Share Price: Frequently Asked Questions
What is the current share price of ZENITH DRUGS LIMIT?
ZENITH DRUGS LIMIT (ZENITHDRUG) trades at ₹41.35 on NSE. Market cap ₹89.95 (Cr). Educational data only.
What is the P/E ratio of ZENITH DRUGS LIMIT?
ZENITH DRUGS LIMIT has a P/E of 21.62x vs industry average 34.89x.
What is the Bull Run score for ZENITH DRUGS LIMIT?
ZENITH DRUGS LIMIT has a Bull Run score of 39.5/100 based on 25+ financial parameters.
Does ZENITH DRUGS LIMIT pay dividends?
ZENITH DRUGS LIMIT has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of ZENITH DRUGS LIMIT?
ZENITH DRUGS LIMIT has ROE of 5.77%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of ZENITH DRUGS LIMIT?
ZENITH DRUGS LIMIT has debt-to-equity of 0.74.
Is ZENITH DRUGS LIMIT a good investment?
Bull Run gives ZENITH DRUGS LIMIT a score of 39.5/100. This is not investment advice — consult a SEBI-registered advisor.